Catalog No.
DHC36902
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1
Clonality
Monoclonal
Target
sIL6R, Interleukin-6 receptor subunit alpha, CD126, IL-6R 1, IL-6R subunit alpha, Membrane glycoprotein 80, gp80, IL6R, IL-6RA, IL-6 receptor subunit alpha, IL-6R-alpha
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P08887
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
Atlizumab, MRA, R-1569, RHPM-1, RO-4877533, CAS: 375823-41-9
Clone ID
Tocilizumab
Tocilizumab: A Review in Rheumatoid Arthritis, PMID: 29094311
Tocilizumab for severe COVID-19: a systematic review and meta-analysis, PMID: 32712333
Tocilizumab: the first interleukin-6-receptor inhibitor, PMID: 18653811
Tocilizumab (Actemra), PMID: 28841363
Tocilizumab for Treatment of Mechanically Ventilated Patients With COVID-19, PMID: 32651997
[COVID-19: Still a place for tocilizumab?], PMID: 33288230
Tocilizumab in Covid-19, PMID: 33356049
Tocilizumab in transplantation, PMID: 32266480
Tocilizumab in Giant Cell Arteritis, PMID: 29570475
Efficacy of tocilizumab treatment in severely ill COVID-19 patients, PMID: 32854738
Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial, PMID: 27156934
Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia, PMID: 32575124
Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes, PMID: 32553536
Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial, PMID: 31469238
Tocilizumab for treating COVID-19: a systemic review and meta-analysis of retrospective studies, PMID: 33051695
Tocilizumab for Covid-19 - The Ongoing Search for Effective Therapies, PMID: 33296566
Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review, PMID: 32940187
Tocilizumab in Autoimmune Encephalitis Refractory to Rituximab: An Institutional Cohort Study, PMID: 27215218
Tocilizumab treatment for new onset refractory status epilepticus, PMID: 30408233
Tocilizumab, PMID: 20065633
Vitamin D: A simpler alternative to tocilizumab for trial in COVID-19?, PMID: 32353742
Effectiveness of tocilizumab in Behcet's disease: A systematic literature review, PMID: 32544751
Tocilizumab for treatment patients with COVID-19: Recommended medication for novel disease, PMID: 33045577
Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade, PMID: 29207939
Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial, PMID: 32333897
Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate), PMID: 29066464
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome, PMID: 29622697
Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia, PMID: 32405160
Effects of tocilizumab on mortality in hospitalized patients with COVID-19: a multicentre cohort study, PMID: 32979572
Tocilizumab: do not be the next chloroquine!, PMID: 32744721
Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis, PMID: 30590833
Tocilizumab improves oxidative stress and endothelial glycocalyx: A mechanism that may explain the effects of biological treatment on COVID-19, PMID: 32822775
Tocilizumab in the treatment of giant cell arteritis, PMID: 29504436
Tocilizumab in Covid-19. Reply, PMID: 33356050
Tocilizumab and COVID-19: a meta-analysis of 2120 patients with severe disease and implications for clinical trial methodologies, PMID: 33244947
Tocilizumab in the treatment of adult rheumatoid arthritis, PMID: 29495891
Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a case-controlled study, PMID: 32569363
Tocilizumab for Giant Cell Arteritis, PMID: 32205653
Tocilizumab mimotope alleviates kidney injury and fibrosis by inhibiting IL-6 signaling and ferroptosis in UUO model, PMID: 32979361
Tocilizumab in isolated polymyalgia rheumatica: A systematic literature review, PMID: 32107035
Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease, PMID: 18784373
Tocilizumab in the Management of COVID-19: A Preliminary Report, PMID: 33358502
Tocilizumab prescribing criteria for COVID-19 patients, PMID: 33079613
Time to Reassess Tocilizumab's Role in COVID-19 Pneumonia, PMID: 33079980
Tocilizumab does not block interleukin-6 (IL-6) signaling in murine cells, PMID: 32365119
Interstitial granulomatous dermatitis following tocilizumab, a paradoxical reaction?, PMID: 32816393
Tocilizumab for treating juvenile idiopathic arthritis, PMID: 26848760
Tocilizumab in patients with severe COVID-19: A single-center observational analysis, PMID: 32628003
Efficacy and Safety of Tocilizumab for Coronavirus Disease 2019 (Covid-19) Patients: A Systematic Review and Meta-analysis, PMID: 33401328
Tocilizumab in Graves ophthalmopathy, PMID: 31493854
For research use only. Not for human or drug use.
